Fox Run Management L.L.C. Trims Position in Enovis Corporation $ENOV

Fox Run Management L.L.C. trimmed its position in Enovis Corporation (NYSE:ENOV) by 15.8% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 23,561 shares of the company’s stock after selling 4,418 shares during the period. Fox Run Management L.L.C.’s holdings in Enovis were worth $739,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in ENOV. T. Rowe Price Investment Management Inc. grew its position in Enovis by 0.7% during the first quarter. T. Rowe Price Investment Management Inc. now owns 6,207,768 shares of the company’s stock valued at $237,199,000 after buying an additional 44,632 shares during the period. Vanguard Group Inc. raised its holdings in Enovis by 11.3% in the 1st quarter. Vanguard Group Inc. now owns 6,107,199 shares of the company’s stock worth $233,356,000 after purchasing an additional 621,069 shares during the period. Dimensional Fund Advisors LP lifted its position in Enovis by 1.0% during the first quarter. Dimensional Fund Advisors LP now owns 2,927,340 shares of the company’s stock valued at $111,852,000 after purchasing an additional 27,894 shares in the last quarter. Royce & Associates LP grew its holdings in Enovis by 0.8% during the first quarter. Royce & Associates LP now owns 2,490,806 shares of the company’s stock valued at $95,174,000 after purchasing an additional 20,230 shares during the period. Finally, Allspring Global Investments Holdings LLC increased its position in Enovis by 191.5% in the second quarter. Allspring Global Investments Holdings LLC now owns 810,771 shares of the company’s stock worth $26,772,000 after buying an additional 532,648 shares in the last quarter. Institutional investors own 98.45% of the company’s stock.

Insider Buying and Selling at Enovis

In other Enovis news, CEO Damien Mcdonald acquired 6,457 shares of the company’s stock in a transaction on Thursday, September 11th. The stock was acquired at an average cost of $30.97 per share, with a total value of $199,973.29. Following the purchase, the chief executive officer directly owned 102,753 shares of the company’s stock, valued at approximately $3,182,260.41. This represents a 6.71% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Bradley J. Tandy bought 3,200 shares of the firm’s stock in a transaction dated Friday, August 22nd. The shares were acquired at an average price of $31.41 per share, for a total transaction of $100,512.00. Following the completion of the transaction, the senior vice president directly owned 43,515 shares in the company, valued at approximately $1,366,806.15. This represents a 7.94% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 12,157 shares of company stock worth $374,760 over the last 90 days. 2.70% of the stock is owned by insiders.

Enovis Price Performance

NYSE:ENOV opened at $28.02 on Monday. The business’s 50-day moving average is $31.33 and its 200 day moving average is $31.45. Enovis Corporation has a 12 month low of $25.47 and a 12 month high of $49.75. The company has a market capitalization of $1.60 billion, a P/E ratio of -1.97 and a beta of 1.67. The company has a current ratio of 2.25, a quick ratio of 1.15 and a debt-to-equity ratio of 0.53.

Enovis (NYSE:ENOV) last issued its quarterly earnings data on Monday, January 8th. The company reported $0.59 earnings per share (EPS) for the quarter. Enovis had a positive return on equity of 6.78% and a negative net margin of 37.80%.The business had revenue of $383.81 million for the quarter. On average, equities research analysts forecast that Enovis Corporation will post 2.79 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently commented on ENOV. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enovis in a research note on Wednesday, October 8th. Needham & Company LLC decreased their target price on shares of Enovis from $57.00 to $49.00 and set a “buy” rating on the stock in a research note on Thursday, August 7th. UBS Group dropped their price target on shares of Enovis from $65.00 to $57.00 and set a “buy” rating for the company in a research report on Friday, August 8th. Canaccord Genuity Group decreased their price objective on shares of Enovis from $70.00 to $58.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Finally, Wells Fargo & Company lifted their target price on shares of Enovis from $41.00 to $42.00 and gave the company an “overweight” rating in a research note on Friday. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $51.17.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.